Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beyond Air, Inc.XAIR · Entity 8379 | Director | November 22, 2024 | November 27, 2024 |
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director · Chairman & CEO · 10% owner | June 30, 2026 | July 01, 2026 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director · Chief Executive Officer | January 01, 2019 | January 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beyond Air, Inc.
Report date November 22, 2024 · Filed November 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.53 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-11-22 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 45,000 |
Reported balance
After 2024-11-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-11-22 · Grant · Acquired 45,000 · Balance 45,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.28 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-11-22 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 40,000 |
Reported balance
After 2024-11-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-11-22 · Grant · Acquired 40,000 · Balance 40,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-11-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 30,000 |
Reported balance
After 2024-11-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-11-22 · Grant · Acquired 30,000 · Balance 30,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-11-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 25,000 |
Reported balance
After 2024-11-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-11-22 · Grant · Acquired 25,000 · Balance 25,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.32 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-11-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 25,000 |
Reported balance
After 2024-11-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-11-22 · Grant · Acquired 25,000 · Balance 25,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 | Direct | 0 |
Reported balance
After 2024-11-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-11-22 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.54 | Direct | 24,000 |
Reported balance
After 2024-11-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-11-22 · Grant · Acquired 24,000 · Balance 24,000 F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 22, 2024, the Issuer's Board of Directors approved an option repricing, effective as of November 22, 2024 (the "Effective Date") reducing the exercise price to $0.54 per share, the closing price of the Issuer's common stock on the Effective Date. All of the other terms of the options remain unchanged.
F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Nuvectis Pharma, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,688,424 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 12,500 · Balance 3,688,424 F1: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Bentsur purchased 12,500 shares for $250,000 in the public offering announced on June 29, 2026.
F2: Includes shares of restricted common stock.
UroGen Pharma Ltd.
Report date January 01, 2019 · Filed January 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 38,113 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 38,113 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.55 · Expires 2027-06-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.67 · Expires 2028-01-10 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the restricted stock units ("RSUs") vested on August 9, 2016 and 2.778% of the remaining RSUs will vest in equal monthly installments thereafter.
F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3: 8.33% of the shares underlying the stock option will vest in equal quarterly installments commencing 3 months after June 28, 2017.
F4: 2.778% of the shares underlying the stock option will vest in equal monthly installments commencing 1 month after January 10, 2018.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 1
1 source rowRow 1 · 2020-06-10 · Other · Disposed 66,346 · Balance 0 F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.92 · Expires 2021-03-08 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-06-10 · Disposition to issuer · Disposed 9,034 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2022-03-09 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-10 · Disposition to issuer · Disposed 18,070 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.78 · Expires 2026-05-25 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-10 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2027-06-19 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-06-10 · Disposition to issuer · Disposed 24,000 · Balance 0 F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with a tender offer made pursuant to an agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"), in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
F2: All options were vested and exercisable as of the effective time of the merger.
F3: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2022 Filed Nov 30, 2022 22:43 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 150 | $7.45 | $1,117.50 |
DisclosureSEC source: 0001104659-22-123312 · tm2231703-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,015,459 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| November 29, 2022 Filed Nov 29, 2022 21:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 150 | $7.45 | $1,117.50 |
DisclosureSEC source: 0001104659-22-122887 · tm2231558-1_4seq1.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,015,309 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| November 28, 2022 Filed Nov 29, 2022 21:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 150 | $7.40 | $1,110.00 |
DisclosureSEC source: 0001104659-22-122887 · tm2231558-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,015,159 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| November 25, 2022 Filed Nov 29, 2022 21:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 150 | $7.38 | $1,107.00 |
DisclosureSEC source: 0001104659-22-122887 · tm2231558-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,015,009 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| November 18, 2022 Filed Nov 21, 2022 13:39 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $7.23 | $3,615.00 |
DisclosureSEC source: 0001104659-22-120514 · tm2231008-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,014,859 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| November 17, 2022 Filed Nov 21, 2022 13:39 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 250 | $7.24 | $1,810.00 |
DisclosureSEC source: 0001104659-22-120514 · tm2231008-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,014,359 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| November 10, 2022 Filed Nov 16, 2022 13:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,000 | $7.07 | $7,070.00 |
DisclosureSEC source: 0001104659-22-119361 · tm2227229-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,014,109 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 12:16 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $7.46 | $3,730.00 |
DisclosureSEC source: 0001104659-22-104928 · tm2227229-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,013,109 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| September 28, 2022 Filed Oct 3, 2022 12:16 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $7.23 | $3,615.00 |
DisclosureSEC source: 0001104659-22-104928 · tm2227229-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012,609 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| September 26, 2022 Filed Sep 27, 2022 12:44 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $7.69 | $3,845.00 |
DisclosureSEC source: 0001104659-22-103162 · tm2226689-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012,109 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 12:44 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,000 | $7.93 | $7,930.00 |
DisclosureSEC source: 0001104659-22-103162 · tm2226689-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,011,609 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,200 | $8.37 | $10,044.00 |
DisclosureSEC source: 0001104659-22-097694 · tm2225158d2_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,010,609 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 12:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $8.11 | $4,055.00 |
DisclosureSEC source: 0001104659-22-097694 · tm2225158d2_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,009,409 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| August 29, 2022 Filed Aug 30, 2022 11:35 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,000 | $9.07 | $9,070.00 |
DisclosureSEC source: 0001104659-22-095830 · tm2224779-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,008,909 F2 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.99 to $9.31. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| August 23, 2022 Filed Aug 30, 2022 11:35 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $9.00 | $4,500.00 |
DisclosureSEC source: 0001104659-22-095830 · tm2224779-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007,909 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 13:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 5,000 | $8.99 | $44,950.00 |
DisclosureSEC source: 0001104659-22-093128 · tm2224247-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007,409 F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| August 18, 2022 Filed Aug 22, 2022 13:00 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 14,426 | $8.58 | $123,775.08 |
DisclosureSEC source: 0001104659-22-093128 · tm2224247-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,002,409 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.55 to $8.60. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| August 11, 2022 Filed Aug 16, 2022 20:05 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 19,669 | $8.40 | $165,219.60 |
DisclosureSEC source: 0001104659-22-091746 · tm2223621-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,987,983 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $8.31 to $8.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 20:44 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 40,000 | $6.53 | $261,104.00 |
DisclosureSEC source: 0001493152-22-018552 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,436 F2 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $6.57, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · acquired: The sale was made to satisfy an Israeli tax obligation resulting from the reporting person's ownership of shares of Advanced Inhalation Therapies (AIT) Ltd., an Israeli corporation, which merged with Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.), a Delaware corporation, on January 13, 2017. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 3,700 | $11.62 | $42,994.00 |
DisclosureSEC source: 0001104659-22-076049 · tm2220119-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,968,314 F2 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $11.60 to $11.70. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 300 | $11.82 | $3,546.00 |
DisclosureSEC source: 0001104659-22-076049 · tm2220119-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,964,614 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| June 24, 2022 Filed Jun 27, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 400 | $12.18 | $4,872.00 |
DisclosureSEC source: 0001104659-22-074544 · tm2219464-1_4seq1.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,964,314 F2 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $12.01 to $12.34. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 200 | $11.40 | $2,280.00 |
DisclosureSEC source: 0001104659-22-074544 · tm2219464-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,963,914 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| June 22, 2022 Filed Jun 27, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 100 | $13.10 | $1,310.00 |
DisclosureSEC source: 0001104659-22-074544 · tm2219464-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,963,714 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 27, 2022 Filed May 31, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $15.74 | $7,870.00 |
DisclosureSEC source: 0001104659-22-066269 · tm2217208-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,963,614 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 26, 2022 Filed May 31, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $15.90 | $7,950.00 |
DisclosureSEC source: 0001104659-22-066269 · tm2217208-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,963,114 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 20, 2022 Filed May 23, 2022 12:32 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,000 | $16.28 | $16,280.00 |
DisclosureSEC source: 0001104659-22-063645 · tm2216562-2_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,962,614 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 19, 2022 Filed May 23, 2022 12:32 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 200 | $18.95 | $3,790.00 |
DisclosureSEC source: 0001104659-22-063645 · tm2216562-2_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,961,614 F1 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 18, 2022 Filed May 19, 2022 14:21 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,000 | $18.49 | $18,490.00 |
DisclosureSEC source: 0001104659-22-062766 · tm2216045d1_4.xml · nonDerivative · entry 4 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,961,414 F4 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $18.45 to $18.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 18, 2022 Filed May 19, 2022 14:21 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 700 | $20.60 | $14,420.00 |
DisclosureSEC source: 0001104659-22-062766 · tm2216045d1_4.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,960,414 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $20.10 to $20.82. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 17, 2022 Filed May 19, 2022 14:21 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 110 | $20.83 | $2,291.30 |
DisclosureSEC source: 0001104659-22-062766 · tm2216045d1_4.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,959,714 F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 17, 2022 Filed May 19, 2022 14:21 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 200 | $19.77 | $3,954.00 |
DisclosureSEC source: 0001104659-22-062766 · tm2216045d1_4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,959,604 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $19.75 to $19.79. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 16, 2022 Filed May 17, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,000 | $19.32 | $19,320.00 |
DisclosureSEC source: 0001104659-22-061753 · tm2215754-1_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,959,404 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $19.00 to $19.68. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 13, 2022 Filed May 17, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 700 | $18.10 | $12,670.00 |
DisclosureSEC source: 0001104659-22-061753 · tm2215754-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,958,404 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.80 to $18.51. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 12, 2022 Filed May 13, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 10,545 | $17.26 | $182,006.70 |
DisclosureSEC source: 0001104659-22-059888 · tm2215423-4_4seq1.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,957,704 F4 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.01 to $17.53. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 12, 2022 Filed May 13, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 600 | $16.12 | $9,672.00 |
DisclosureSEC source: 0001104659-22-059888 · tm2215423-4_4seq1.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,947,159 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.90 to $16.33. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| May 12, 2022 Filed May 13, 2022 12:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 1,100 | $14.88 | $16,368.00 |
DisclosureSEC source: 0001104659-22-059888 · tm2215423-4_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,946,559 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.73 to $15.45. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:46 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042813 · tm2211420-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,945,459 F1 · shares: The restricted stock units will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025. F2 · balance_after: Includes 96,759 shares of restricted stock and 120,000 restricted stock units. Read SEC document |
| March 28, 2022 Filed Mar 29, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 4,000 | $7.05 | $28,200.00 |
DisclosureSEC source: 0001104659-22-039119 · tm2210671-1_4seq1.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,825,459 F1 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| March 17, 2022 Filed Mar 18, 2022 12:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 7,000 | $7.63 | $53,410.00 |
DisclosureSEC source: 0001104659-22-035347 · tm229700-1_4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,821,459 F1 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 13:33 UTC | Beyond Air, Inc. XAIR · Entity 8379 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.87 | $0.00 |
DisclosureSEC source: 0001493152-22-006146 · ownership.xml · derivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option will vest as to 25% of the shares of common stock underlying the option on December 31, 2022, with the remainder vesting in equal annual installments on December 31 of each of the three ensuing years thereafter until vested in full. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 14:15 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 8,000 | $5.88 | $47,040.00 |
DisclosureSEC source: 0001104659-22-023547 · tm226759d1_4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,814,459 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $5.50 to $6.10. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 14:15 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 8,500 | $6.34 | $53,890.00 |
DisclosureSEC source: 0001104659-22-019955 · tm226323d1_4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,806,459 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $6.27 to $6.35. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 18:13 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 6,000 | $8.25 | $49,500.00 |
DisclosureSEC source: 0001104659-22-013142 · tm225864-1_4.xml · nonDerivative · entry 4 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,797,959 F2 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 18:13 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 14,000 | $3.93 | $55,020.00 |
DisclosureSEC source: 0001104659-22-013142 · tm225864-1_4.xml · nonDerivative · entry 3 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,791,959 F4 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.60 to $4.25. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 18:13 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 12,500 | $3.89 | $48,625.00 |
DisclosureSEC source: 0001104659-22-013142 · tm225864-1_4.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,777,959 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.83 to $3.95. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 18:13 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 200,000 | $5.00 | $1,000,000.00 |
DisclosureSEC source: 0001104659-22-013142 · tm225864-1_4.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,765,459 F1 · price: Reflects the price of shares of common stock purchased by Mr. Bentsur in Nuvectis Pharma's initial public offering. F2 · balance_after: Includes 96,759 shares of restricted stock. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 22:19 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 6,464 | $13.99 | $90,431.36 |
DisclosureSEC source: 0001493152-21-029937 · ownership.xml · nonDerivative · entry 2 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,436 F1 · acquired: As previously reported, on November 22, 2021, shares of common stock, par value $0.0001 per share, of Beyond Air, Inc. (the "Company") were issued to the reporting person in connection with the exercise of a warrant to purchase 50,000 shares of common stock of the Company for $3.66 a share on a cashless exercise basis, resulting in the Company's withholding of 12,536 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 37,464 shares of common stock of the Company. These transactions were exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3. On November 24, 2021, the reporting person sold the 37,464 shares of common stock of the Company acquired in connection with the warrant exercise. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 22:19 UTC | Beyond Air, Inc. XAIR · Entity 8379 | SaleCommon Stock | 31,000 | $13.44 | $416,640.00 |
DisclosureSEC source: 0001493152-21-029937 · ownership.xml · nonDerivative · entry 1 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,900 F2 · price: The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.9394 to $13.9389, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · acquired: As previously reported, on November 22, 2021, shares of common stock, par value $0.0001 per share, of Beyond Air, Inc. (the "Company") were issued to the reporting person in connection with the exercise of a warrant to purchase 50,000 shares of common stock of the Company for $3.66 a share on a cashless exercise basis, resulting in the Company's withholding of 12,536 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 37,464 shares of common stock of the Company. These transactions were exempt from Section 16(b) of the Securities Exchange Act of 1934 pursuant to Rule 16b-3. On November 24, 2021, the reporting person sold the 37,464 shares of common stock of the Company acquired in connection with the warrant exercise. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 21:15 UTC | Beyond Air, Inc. XAIR · Entity 8379 | Exercise / conversionWarrants (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001493152-21-029833 · ownership.xml · derivative · entry 3 BENTSUR RON · CIK 0001251213 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2022-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.